학술논문

[티시바이오 주식회사]

수지상세포 학술논문

많은 의사들이 보다 더 좋은 치료결과를

만들기 위해치료효과를 분석하고

연구에 매진하고 있습니다.

수지상세포를 이용한 암 백신요법은

전 세계 많은 연구진에 의해

연구되어 온 과학적이고 검증된

암 치료법입니다.

위암/식도암/대장암 Stomach/Esophageal/Colon Cancer

Chang AE, et al(2002), A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer, Clin Cancer Res, (4) :1021-32.

Fong L, et al(2001), Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy, Proc Natl Acad Sci US A, ; 98 (15) :8809-14.

Homma S, et al(2005), Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Clin Cancer Res, ; 11 (8) :3017-24.

Itoh T, et al(2002), Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen, Cancer Immunol Immunother, (2) :99-106.

Kono K, et al(2002), Dendritic cells pulsed with Her-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer, Clin Cancer Res, (11) :3394-400.

Liu KJ, et al(2004), Generation of carcinoembryonic antigen (CEA)-specific T-cell response in HLA-A0201 and HLA-A2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides, Clin Cancer Res, (8) :2645-51.

Loveland BE, et al(2005), Mannan-MUC1-pulsed dendritic cell immunotherapy : A phase I trial in patients with adenocarcinoma, Anticancer Res, (6A) :3771-6.

Mazzolini G, et al(2005), Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas, J Clin Oncol, (5) :999-1010.

Morse MA, et al(2005), Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules, Clin Cancer Res, (8) :3017-24.

Morse M, et al(2003), Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA, Cancer Investigation, (3) : 341-349.

Morse M, et al(1999), A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen, Clin Cancer Res, (6) :1331-8.

Sakakibara M, et al(2011), Comprehensive immunological analyses of colorectal cancer patients in the phase I / II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide, Cancer Immunol Immunother

Sadanaga N, et al(2001), Dendritic cell vaccination with mage peptide is a novel therapeutic approach for gastrointestinal carcinomas, Clin Cancer Res, (8) :2277-84.

Toungouz M, et al(2001), Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol, (6) :937-43.

두경부암 Head and Neck Cancer

Lin C, et al(2002), Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8 + T-cell immunity and may lead to tumour regression in patients with EBV-positive nasopharyngeal carcinoma, Cancer Res, (23) :6952-8.

Toungouz M, et al(2001), Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors, J Leukoc Biol, (6) :937-43.

뇌종양 Brain Tumor

Caruso DA, et al(2004), Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer, Neuro Oncol, (3) :236-46.

Chang CN.et.al(2011), A Phase I / II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma, J Clin Neurosci, (8) :1048-54.

Chang AE, et al(2002), A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer, Clin Cancer Res, (4) :1021-32.

Homma S, et al(2005), Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12, Eur J Clin Invest, (4) :279-86.

John H.Sampson.et.al(2009), An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme, Mol Cancer Ther, (10) :2773-9.

Khan JA et al(2006), Dendritic cell therapy with improved outcome in glioma multiforme - a case report. J Zhejiang Univ Sci B, (2) :114-7.

Kikuchi T, et al(2001), Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells, Cancer Immunol Immunother, (7) :337-44.

Kikuchi T, et al(2004), Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12, J Immunother, (6) :452-9.

Liau LM, et al(2005), Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment, Clin Cancer Res, (15) :5515-25.

Mayordomo JI, et al(2007), Results of a pilot trial of immunotherapy with dendritic cells pulsed w ith autologous tumor lysates in patients with advanced cancer, Tumori, (1) :26-30.

Steven De Vleeschouwer, et al(2008), prostoperative Ajuvant Dentritic cell-based Immunotherapy In patients with Relapsed Glioblastomo Multiforme, Clin Cancer Res, (10) May3098-3104. Walker DG.et al(2008), Results of phase 1dendritic cell vaccines trial for malignant astrocytoma : potential interaction with ajuvant chemotherapy, J Clin Neurosci, (2) :114-21.

Yamanaka R, et al(2003), Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses : results of a clinical phase I / II trial, Br J Cancer, (7) :1172-9.

Yamanaka R, et al(2005), Clinical eval‎uation of dendritic cell vaccination for patients with recurrent glioma : results of a clinical phase I / II trial, Clin Cancer Res ,(11) :4160-7.

Yu JS, et al(2001), Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration, Cancer Res, 61 (3) :842-7.

Yu JS, et al(2004), Vaccination with tumour lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma, Cancer Res, (14) :4973-9.

췌장암/담낭암/간암 Pancreatic Gallbladder Liver Cancer

Chi KH, et al(2005), Combination of conformal radiotherpay and intratumoural injection of adoptive dendritic cell immunotherapy in refractory hepatoma, J Immunother, (2):129-35.

Dohnal AM, et al(2007), Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer, Cytotherapy, (8):755-70.

Iwashita Y, et al(2003), A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer, Cancer Immunol Immunother, (3):155-61.

Morse M, et al(1999), A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expres, Clin Cancer Res, (6):1331-8.

Mazzolini G,et al(2005), Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas, J Clin Oncol, (5):999-1010.

Pecher G, et al(2002), Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial, Cancer Immunol Immunother, (11-12):669-73.

Palmer DH, et al(2009), A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma, Hepatology, (1):124-32.

Schott M, et al(2001), Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma, Clin Endocrinol, (Oxf) (2):271-7.

유방암 Breast Cancer

Avigan D, et al(2004), Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses, Clin Cancer Res, (14):4699-708.

Brossart P, et al(2000), Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, (9):3102-8.

Dees CE, et al(2004), Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer, Cancer Immunol Immunother, (9):777-85.

Homma S, et al(2005), Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12, Eur J Clin Invest, (4):279-86.

Katano M, et al(2005), Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas, Anticancer Res, (6A):3771-6.

Kobayashi T, et al(2001), Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case, Surg Today, (6):513-6.

Loveland BE, et al(2006), Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma, Clin Cancer Res, (3 Pt 1):869-77.

Mayordomo JI, et al(2007), Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer. Tumori, (1):26-30.

Morse M, et al(1999), A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen, Clin Cancer Res, (6):1331-8.

Park JW, et al(2007), Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer, J Clin Oncol, (24):3680-7.

Pecher G. et al(2002), Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial, Cancer Immunol Immunother, (11-12):669-73.

Svane IM, et al(2007), Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers, Cancer Immunol Immunother, (9):1485-99.

Svane IM, et al(2004), Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study, Cancer Immunol Immunother, (7):633-41.

Triozzi PL, et al(2000), Intratumoural injection of dendritic cells derived in vitro in patients with metastatic cancer, Cancer, (12):2646-54.

Vonderheide RH, et al(2004), Vaccination of cancer patients against telomerase induces functional antitumour CD8+ T Lymphocytes, Clin Cancer Res, (3):828-39.

폐암 Lung Cancer

Chang GC, et al(2005), A pilot trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma, Cancer, 103(4):763-71.

Fong L. et al(2001), Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy, Proc Natl Acad Sci U S A, (15):8809-14.

Hirschowitz EA, et al(2007), Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells, Lung Cancer, (3):365-72.

Ishikawa A, et al(2005), A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer, Clin Cancer Res, (5):1910-7.

Itoh T, et al(2002), Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen, Cancer Immunol Immunother, (2):99-106.

Katano M, et al(2005), Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas, Anticancer Res, (6A):3771-6.

Loveland BE, et al(2006), Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma, Clin Cancer Res, (3 Pt 1):869-77.

Mayordomo JI, et al(2007), Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer, Tumori, (1):26-30.

Morse MA, et al(2005), Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules, Clin Cancer Res, (8):3017-24.

Perroud MW Jr, et al(2011), Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study, J Exp Clin Cancer Res, :65.

Toungouz M, et al(2001), Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors, J Leukoc Biol, (6):937-43.

신장암 Kidney Cancer

Arroyo JC, et al(2004), Immune responses induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cells vaccines, J Clin Immunol, (1):86-96.

Dall'Oglio MF,et al(2011), Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy, Int Braz J Urol, (2):180-5; discussion 185-6.

Geiger J, et al(2001), Vaccination of pediatric solid tumour patients with tumour lysate-pulsed dendritic cells can expand specific T cells and mediate tumour regression, Cancer Res, (23):8513-9.

Holtl L, et al(2005), Allogeniec dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide, Cancer Immunol Immunother, (7):663-70.

Holtl L, et al(2002), Immunotherapy of metastatic renal cell carcinoma with tumour lysate-pulsed autologous dendritic cells, Clin Cancer Res, (11):3369-76.

Kim JH, et al(2007), Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma, Clin Immunol, (3):257-67.

Kugler A, et al(2000), Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids, Nat Med, (3):332-6.

Mackall CL, et al(2008), A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas, Clin Cancer Res, (15):4850-8.

Mayordomo JI, et al(2007), Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer, Tumori, (1):26-30.

Marten A, et al(2003), Allogeneic dendritic cells fused with tumor cells: Pre clinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma, Hum Gene Ther, (5):483-94.

Marten A, et al(2002), Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. 2002, Cancer Immunol Immunother, (11-12):637-44.

Nair SK, et al(1999), Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA, Int J Cancer, (1):121-4

Pandha H, et al(2004), Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study, BJU Int, (3):412-8.

Su Z, et al(2003), Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumour RNA-transfected dendritic cells, Cancer Res, (9):2127-33.

Wierecky J et al(2006), Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients, Cancer Res, (11):5910-8.

Holtl L, et al(1999), Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells, J Urol, (3):777-82.

자궁/난소암 Uterine/Ovarian Cancer

Loveland BE, et al(2006), Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma, Clin Cancer Res, (3 Pt 1):869-77.

Homma S, et al(2005), Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12, Eur J Clin Invest, (4):279-86.

Hernando JJ, et al(2002), Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynecological malignancies: clinical and immunological eval‎uation of a phase I trial, Cancer Immunol Immunother, (1):45-52

Brossart P, et al(2000), Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, (9):3102-8.

Morse M, et al(1999), A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expres, Clin Cancer Res, (6):1331-8.

전립선암 Prostate Cancer

Barrou B, et al(2004), Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA, Cancer Immunol Immunother, (5):453-60.

Burch PA, et al(2000), Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer, Clin Cancer Res, (6):2175-82.

Fuessel S et al(2006), Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial, Prostate, (8):811-21.

Fong L, et al(2001), Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy, J Immunol, (12):7150-6.

Fong L, et al(2001), Dendritic cells injected via different routes induce immunity in cancer patients, J Immunol, (6):4254-9.

Hildenbrand B, et al(2007), Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study, Prostate, (5):500-8.

Heiser A, et al(2002), Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors, J Clin Invest, (3):409-17.

Lawrence Fong et al(2001) Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy, J Immunol, (12):7150-6.

LJ Mu, et al(2005), Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients, Br J Cancer, (7):749-56.

Lodge PA, et al(2000), Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial, Cancer Res, (4):829-33.

Murphy GP, et al(1999), Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase 2 prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, (1):73-8.

Murphy GP, et al(2000), Higher dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients, Prostate, (1):59-62.

Murphy GP, et al(1999), Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment, Prostate, (1):54-9.

Pandha H, et al(2004), Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study, BJU Int, (3):412-8.

Small EJ, et al(2000), Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells, J Clin Oncol, (23):3894-903.

Thomas-Kaskel AK, et al(2006), Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival, Int J Cancer, (10):2428-34.

Tjoa BA, et al(1999), Follow-up eval‎uation of a phase II prostate cancer vaccine trial, Prostate, (2):125-9.

Vonderheide RH, et al(2004), Vaccination of cancer patients against telomerase induces functional antitumour CD8+ T Lymphocytes, Clin Cancer Res, (3):828-39.

소아암 Childhood Cancer

Dohnal AM, et al(2007), Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer, Cytotherapy, (8):755-70.

Dagher R, et al(2002), Pilot trial of tumour-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent ewing sarcoma and alveolar rhabdomyosarcoma: a inter-institute NIH study, Med Pediatr Oncol, (3):158-64

Geiger J, et al(2001), Vaccination of pediatric solid tumour patients with tumour lysate-pulsed dendritic cells can expand specific T cells and mediate tumour regression, Cancer Res, (23):8513-9.

Geiger J, et al(2000), Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells, Lancet, (9236):1163-5.

Mackall CL, et al(2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas, Clin Cancer Res, (15):4850-8.

악성흑색종 Malignant melanoma

Akiyama Y, et al(2005), Clinical pesponse in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells, J Transl Med, (1):4.

Andersen MH, et al(2001), Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression, Int J Cancer, (6):820-4.

Banchereau J, et al(2001), Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res, (17):6451-8.

Banchereau J, et al(2005), Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells from CD34+ progenitors and activated with type I interfereon, J Immunother, (5):505-16.

Bedrosian I, et al(2003), Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients, J Clin Oncol, (20):3826-35.

Cornforth A,et al(2011), Autologous peripheral blood mononuclear cell recognition of autologous proliferationg tumor cells in the context of a patient-specific vaccine trial, J Biomed Biotech, Epub. Chang AE, et al(2002), A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer, Clin Cancer Res, (4):1021-32.

De Vries IJ, et al(2005), Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome,J Clin Oncol, (24):5779-87.

Di Nicola M, et al(2004), Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+ derived dendirtic cell vaccination: A phase I trialin metastatic melanoma, Clin Cancer Res, (16):5381-90

De Vries IJ, et al(2003), Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients, Clin Cancer Res, (14):5091-100.

Escobar A, et al(2005), Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients, Clin Exp Immunol , (3):555-68.

Fay JW, et al(2006), Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. Cancer Immunol Immunother, Cancer Immunol Immunother, (10):1209-18.

Homma S, et al(2005), Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12, Eur J Clin Invest, (4):279-86.

Hersey P, et al(2004), Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma, Cancer Immunol Immunother, (2):125-34.

Hersey P, et al(2008), Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanom, Cancer Immunol Immunother, (7):1039-51.

Jonuleit H, et al(2001), A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection, Int J Cancer, (2):243-51.

Lopez MN. Lopez et al(2009), Prolonged Survival of Dendritic Cell?Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells, J Clin Oncol, (6):945-52.

Linette GP, et al(2005), Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity, Clin Cancer Res, (21):7692-9.

Mackensen A, et al(2000), Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells, Int J Cancer, (3):385-92.

Mayordomo JI, et al(2007), Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer, Tumori, (1):26-30.

Nagayama H, et al(2003), Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2, Melanoma Res, (5):521-30.

Nakai N, et al(2006), Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells, J Dermatol, (7):462-72.

Ridolfi L,et al(2010), Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis, Clin Dev Immunol, 2010;2010:504979, Epub. Ribas A,et al(2010), Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma, J Transl Med, :89.

Ridolfi R, et al(2006), Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients, J Transl Med, 4:36

Schuler-Thurner B, et al(2002), Rapid induction of tumor-specific type1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells, J Exp Med, (10):1279-88.

Slingluff CL Jr, et al(2003), Clinical and Immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells, J Clin Oncol, (21):4016-26.

Salcedo M, et al(2006), Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate, Cancer Immunol Immunother, (7):819-29.

Schuler-Thurner B, et al(2000), Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells, J Immunol, (6):3492-6. Toungouz M, et al(2001), Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors, J Leukoc Biol, (6):937-43.

Trefzer U, et al(2000), Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma, Int J Cancer, (5):618-26.

Triozzi PL, et al(2000), Intratumoural injection of dendritic cells derived in vitro in patients with metastatic cancer, Cancer, (12):2646-54.

Trefzer U, et al(2004), Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients, Int J Cancer, (5):730-40.

Trefzer U, et al(2005), Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results, Vaccine, (17-18):2367-73.

von Euw EM, et al(2008), A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression, J Transl Med, :6.

Vilella R, et al(2004), Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterogenous melanoma cell line lysate, Cancer Immunol Immunother, (7):651-8.

Wei Y, et al(2006) Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses, Int J Oncol, (3):585-93.

백혈병/형질세포종양 Leukemia/plasma Cell Tumor

Curti A, et al(2007), Phase I / II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides, Br J Haematol, (3) :415-24.

Cull C, et al(1999), Generation of anti-ideotype immune responses following vaccination with ideotype-protein pulsed dendritic cells in myeloma, Br J Haematol, (3) :648-55.

Kitawaki T.et al(2011), A phase I / IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate, Br J Haematol, (6) : 796 - 9.

Lim SH, et al(1999), Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma, Int J Cancer, (2) :215-22.

Ossenkoppele GJ, et al(2003), Vaccination of chronic myeloid leukemia with autologous in vitro cultured leukemic dendritic cells, Leukemia, (7) :1424-6.

Reichardt VL, et al(2003), Idiotype vaccination of multiple myleoma patients using monocyte-derived dendritic cells, Haematologica, (10) :1139-49.

Reichardt VL, et al(1999), Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study, Blood, (7) :2411-9.

Titzer S, et al(2000), Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells : immunological and clinical aspects, Br J Haematol, (4) :805-16.

Viggo F. et al(2010), Van Tendelooa at el.Induction of complete and molecular remissions in acute myeloid leukemia by Wilms 'tumor 1antigen-targeted dendritic cell vaccination, Proc Natl Acad Sci USA, (31) : 13824-9.

Yi Q, et al(2002), Optimizing dendritic cell-based immunotherapy in multiple myeloma, Br J Haematol, (2) :297-305.

악성림프종 Malignant Lymphoma

Hus I, et al(2005), Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia, Leukemia, (9) :1621-7.

Hsu FJ, et al(1996), Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nat Med, (1) :52-8.

Maier T, et al(2003) Vaccination of patients with cutaneous T cell lymphoma using intranodal injection of autologous tumour-lysate-pulsed dendritic cell, Blood, (7) :2338-44.

Timmerman J. et al(2002), Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma : clinical and immune responses in 35 patients, Blood, (5) :1517-26.

세계가 인정하는 수지상세포백신치료 박셀®의 논문발표

박셀의 임상연구는 미국, 유럽 세계유명학회지

등에 게제 되었고현재도 지속적으로 꾸준하게

임상논문이 발표되고 있습니다.

일본 세렌크리닉병원그룹의 의료진과 연구진은

항상 암 치료에 있어 매일매일

연구에 몰두하며 보다 더 진보된

암 치료에 매진하고 있습니다.

치료상담 1644-8475